Antithymocyte antiserum therapy in myasthenia gravis.
The therapeutic effect of goat anti-human thymocyte antiserum globulin (ATG) was assessed in 10 patients with myasthenia gravis. Prolonged, low dose therapy was used with 1-0--1-6 grams protein administered intramuscularly over a 28-73 day period. Varying degrees of therapeutic response were noted in 8 patients. Fllow-up examinations for over 5 years have been maintained and relapse rates determined. The clinical criteria for aptients selection and characteristics of therapeutic response are presented.